Hubbry Logo
PathergyPathergyMain
Open search
Pathergy
Community hub
Pathergy
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Pathergy
Pathergy
Pathergy
View on Wikipedia
from Wikipedia

Pathergy is a skin condition in which a minor trauma such as a bump or bruise leads to the development of skin lesions or ulcers that may be resistant to healing. Pathergy can also lead to ulcerations at the site of surgical incisions. Pathergy is seen with both Behçet's disease and pyoderma gangrenosum.[1] A highly similar phenomenon known as the Koebner phenomenon occurs in autoimmune diseases such as psoriasis and systemic lupus erythematosus, among others.

Doctors looking toward a diagnosis of Behçet's disease may attempt to induce a pathergy reaction with a test known as a "skin prick test".[2] The inflammation and ulceration that occurs as a result of pathergy in pyoderma gangrenosum often responds to systemic steroid therapy.

The pathergy reaction is a unique feature of Behçet's disease and, according to the International Study Group for Behcet's Disease, is among the major criteria required for the diagnosis. Different positive pathergy reaction rates in BD have been reported worldwide. When BD-positive groups are studied for pathergy reaction, the pathergy-positive and pathergy-negative BD groups showed a similar male: female ratio, age at disease onset, and mean disease duration. They also exhibited similar HLA-B51 levels and a similar frequency of oral ulcerations in close family members. The mucocutaneous manifestations, systemic disease expression, and severity score were similar in patients with and without the pathergy reaction. The presence of a positive pathergy reaction is not associated with an increased risk for specific mucocutaneous or systemic manifestations of the disease, and probably does not predict a more severe disease course.[3]

It is also important to note that, while a positive pathergy reaction helps to confirm a specific Behçet's disease diagnosis, a negative reaction does not invalidate a BD diagnosis, because the disease process has to be active at the time of the skin prick test to produce a pathergy reaction. Differences in positive/negative pathergy and severity of the reaction depend on disease activity, ethnicity, type of needle used for the prick test, among other factors.[2]

Pathergy test is done both orally and cutaneous.

Orally, the lower lip is the site of testing. Appearance of any ulcer or papule indicates a positive pathergy reaction.

Cutaneous sites are the flexor forearm.

Epidemiology

[edit]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Pathergy

View on Grokipedia
from Grokipedia
Pathergy is a hyperreactivity of the skin characterized by an exaggerated inflammatory response to minor trauma, such as a needle prick or abrasion, leading to the development of sterile pustules, papules, or ulcers at the injury site within 24 to 48 hours. This nonspecific reaction was first described in 1937 and manifests as erythematous induration or pustule formation, often resolving within 3 to 4 days without intervention. The phenomenon is most prominently associated with , a chronic multisystem affecting mucocutaneous, ocular, vascular, and neurological systems, where it serves as a key diagnostic criterion in international classification schemes, including the International Study Group criteria. Pathergy also occurs in other neutrophilic dermatoses, such as (affecting 25–50% of cases) and Sweet's syndrome, as well as rarely in conditions like chronic myeloid leukemia or post-interferon therapy. Its prevalence varies geographically, with higher positivity rates (up to 84% in Turkish populations) along the ancient regions and lower rates (around 7–10%) in Northern European cohorts, reflecting genetic and environmental influences like associations in BD. Diagnosis relies on the pathergy test, a simple procedure involving a sterile 20- to 21-gauge needle prick (3–5 mm depth) on the volar , with evaluation at 24–48 hours for a positive response defined as a ≥2 mm , any pustule, or erythematous induration; an oral variant pricks the lower submucosa to detect ulcerative lesions. Despite its specificity (up to 98.4% for BD), the test's sensitivity has declined since the 1980s, potentially due to variations in needle type, skin sterilization, or disease evolution; recent studies as of 2023 have explored modifications like incorporating antigens to improve sensitivity, limiting its utility for monitoring disease activity. Mechanistically, pathergy involves dysregulated innate immunity, with neutrophil infiltration, Th1 release (e.g., IL-8, TNF-α), and possible microbial triggers like Streptococcus sanguinis antigens exacerbating inflammation. Management focuses on avoiding trauma and treating underlying conditions with corticosteroids, immunosuppressants, or biologics like anti-TNF agents, though no specifically addresses pathergy.

Definition and Pathophysiology

Definition

Pathergy refers to a hyper-reactivity of the skin and mucous membranes to minor trauma, eliciting an exaggerated inflammatory response that typically manifests as a , pustule, or ulceration appearing 24 to 48 hours after the injury. This phenomenon represents an abnormal tissue response where even trivial stimuli, such as a needle prick or scratch, provoke disproportionate at the site. The term "pathergy" originates from early 20th-century describing altered tissue reactivity to stimuli, with its modern dermatological usage first detailed in by Blobner in the context of heightened sensitivity. Unlike normal , which entails a regulated sequence of , proliferation, and remodeling to restore tissue , pathergy involves sterile, non-infectious driven by mechanisms rather than pathogen invasion. It is particularly linked to systemic disorders like , where this hyper-reactivity contributes to diagnostic considerations.

Underlying Mechanisms

Pathergy represents a hyperreactive inflammatory response to minor trauma, primarily driven by dysregulation in the . In susceptible individuals, triggers excessive activation of innate immune pathways, leading to heightened recruitment and infiltration at the site of trauma. , as the predominant early responders, exhibit enhanced , , and activation, resulting in the release of and proteases that contribute to tissue damage and perpetuate . This process is characterized by a dense perivascular and interstitial infiltrate, peaking within 24 hours post-trauma, which distinguishes pathergy from typical responses. Central to this hyperactivity are pro-inflammatory cytokines that amplify the inflammatory cascade following trauma. and other resident cells release interleukin-8 (IL-8) and tumor factor-alpha (TNF-α) in response to damage-associated molecular patterns, promoting further migration and activation of downstream signaling via Toll-like receptors (TLRs). Elevated mRNA expression of IL-8 and TNF-α has been observed specifically at pathergy sites, sustaining the non-specific hyperinflammatory state and leading to prolonged tissue injury. These cytokines also facilitate interactions between innate and adaptive immune components, though the innate response predominates in the acute phase. Genetic factors, particularly the HLA-B51 allele, confer susceptibility to pathergy by modulating thresholds, with stronger associations noted in populations of Mediterranean descent where pathergy positivity rates are higher. This allele influences and T-cell activation, potentially lowering the barrier for innate immune overreaction to trauma. Additionally, plays a key role, as trauma-induced expression of adhesion molecules such as intercellular adhesion molecule-1 () and on endothelial cells increases and facilitates inflammatory cell . This heightened permeability exacerbates and leukocyte infiltration, linking pathergy to systemic vasculitic processes often seen in .

Clinical Features

Skin Involvement

Skin pathergy manifests as a hyperreactive response to minor trauma, typically resulting in the formation of a sterile pustule or an erythematous measuring at least 2 mm in diameter at the site of injury. This reaction peaks within 24 to 48 hours after the inciting event and usually resolves within 4 to 5 days, though the heightened sensitivity may lead to persistent or recurrent lesions upon repeated minor traumas. Common triggers include needle pricks from or injections, as well as mechanical irritants such as or abrasions. In severe cases, the inflammatory response can progress to ulceration, particularly in individuals with underlying conditions like . Histologically, the affected skin shows neutrophilic infiltration in the without evidence of infectious agents, often accompanied by perivascular mixed inflammatory cells including lymphocytes. This sterile neutrophilic process underscores the noninfectious, nature of the phenomenon. The response tends to be more pronounced in areas with thinner skin, such as the forearms, compared to thicker regions like the .

Mucosal Involvement

Mucosal pathergy involves the exaggerated inflammatory response in mucous membranes to minor trauma, resulting in ulceration or erosions that are distinct from but related to the skin pathergy phenomenon described elsewhere. Common triggers include dental procedures, such as extractions or restorations, during medical interventions, and everyday oral irritations like accidental biting. These mucosal reactions tend to be more severe, with deeper tissue involvement and prolonged healing times compared to cutaneous lesions, often lasting 1 to 4 weeks or longer. In the oral cavity, pathergy typically presents as recurrent aphthous-like ulcers following trauma, such as from biting the lip or cheek or during orthodontic adjustments. Genital mucosa is also frequently affected, where friction from sexual activity, clothing, or procedures like wax epilation can induce painful ulcers on the vulva, vagina, penis, or scrotum. These lesions are characteristically sterile, lacking infectious etiology despite their resemblance to herpetic or aphthous stomatitis, and they cause significant pain that may impair eating, speaking, or daily activities. Recurrence is common, with new episodes triggered by repeated minor insults to the same sites. The oral pathergy test, used to assess mucosal hyper-reactivity, involves pricking the lip or palate mucosa with a sterile needle and evaluating for or formation after 24 to 48 hours. A positive response, defined as the appearance of such a , is more common in patients than in controls, demonstrating its specificity. However, this test lacks the standardization of the skin pathergy procedure, limiting its widespread adoption.

Diagnosis

The Pathergy Test Procedure

The pathergy test is conducted under aseptic conditions to assess hyper-reactivity by inducing minor trauma with a sterile needle. A disposable needle, typically 20- to 25-gauge, is used to minimize risk from blood-borne pathogens. The on the volar aspect of the is selected as the test site, avoiding visible veins and ensuring the area is hairless for clear observation. Three to five puncture sites are marked, spaced at least 2 cm apart, to allow independent evaluation. The procedure begins with gentle cleaning of the skin using plain water or minimal alcohol swab, as aggressive disinfection with agents like can reduce test positivity by altering local immune responses. At each site, the needle is inserted bevel-up at a 45-degree angle to a depth of 2 to 5 mm, often with a slight twisting motion to standardize trauma, though this is optional. The needle is withdrawn without applying pressure to the site, and no bandages are used to prevent interference with the response. The entire process takes less than 5 minutes and is performed by a trained . Post-procedure, the sites are examined at 24 hours and again at 48 hours for signs of reaction, with photographs recommended for documentation. Patients are instructed to avoid direct trauma, , or topical applications to the test areas during this period to ensure accurate assessment. Regional variations exist in technique: the Japanese method employs multiple superficial pricks (often 4-6 with a 26-gauge needle) for broader sampling, while the Turkish method favors fewer (2-3) but deeper insertions (up to 5 mm with a 20-gauge needle) to enhance sensitivity in high-prevalence populations. An oral pathergy test variant assesses mucosal involvement by pricking the of the lower using a 20-gauge blunt disposable needle, with evaluation at 24-48 hours for ulcerative responses. This is performed similarly under aseptic conditions but requires careful avoidance of the lip's . Precautions include obtaining due to the potential for inducing persistent lesions at test sites, and deferring the test in cases of active infections or recent trauma to prevent confounding results. Disposable needles are mandatory to eliminate cross-contamination risks.

Interpretation and Limitations

A positive pathergy test result is characterized by the formation of an erythematous or pustule with a of at least 2 mm at the site of needle prick, typically evaluated 24 to 48 hours post-procedure, in the absence of any signs of such as induration or . The test is typically performed on the volar aspect of the , with a positive result if a reaction occurs at one or more puncture sites, reflecting systemic hyperreactivity rather than localized response. This interpretation supports diagnostic consideration in contexts like but requires correlation with clinical features, as isolated positivity lacks specificity for any single condition. The diagnostic utility of the pathergy test is tempered by its variable performance metrics. Historically, it exhibited a sensitivity of 60-70% among patients with in endemic regions, aiding criteria; however, contemporary data show a decline to around 40%, linked to , shifts in , and evolving that diminish hyperreactivity expression. Specificity is generally high (over 90%) in low-prevalence settings but decreases outside endemic areas, where false positives in individuals from high-prevalence regions occur, potentially reflecting shared genetic or environmental factors rather than . These metrics underscore the test's supportive rather than definitive role, with positivity more frequent in younger males and early disease stages. Key limitations further constrain the pathergy test's reliability. Inter-observer variability arises from subjective assessment of size and , with studies showing discordance rates up to 20% between blinded evaluators, even under standardized conditions. Moreover, reduced reactivity is observed with advancing age, as positivity rates drop below 30% in patients over 50, and prior use can suppress responses, increasing false negatives by altering inflammatory pathways. These factors highlight the need for cautious application, particularly in atypical or treated cases. Emerging alternatives aim to address these shortcomings through non-invasive approaches. Genetic testing for the allele, a well-established present in 50-80% of Behçet's cases in susceptible populations, offers a for predisposition without procedural risks, though its positive predictive value remains limited (odds ratio 5-6) and requires integration with clinical criteria. Other investigational , such as serum levels of endothelial markers or cytokines, are under evaluation but lack the established utility of HLA-B51 typing for routine screening.

Associated Conditions

Behçet's Disease

Pathergy was first notably described in patients with along the ancient regions, where the condition shows higher prevalence, contributing to its early recognition as a distinctive clinical feature that supports timely diagnosis. In the diagnostic framework established by the International Study Group for in 1990, pathergy serves as a key inclusion criterion; a positive skin pathergy test, alongside recurrent oral ulceration and at least two other manifestations such as genital ulceration, ocular lesions, or lesions, is required for classification in applicable cases. Among patients with , pathergy positivity occurs in 50-80% of cases, particularly in endemic areas like , and it correlates with heightened disease activity as measured by clinical scores. This hyperreactivity reflects underlying characteristic of the in Behçet's disease. Clinically, a positive pathergy test is associated with ocular involvement, such as anterior and posterior , though some studies indicate a lower likelihood in pathergy-positive patients, indicating a higher for vision-threatening complications, though associations with neurological manifestations are less consistent.

Other Disorders

Pathergy, characterized by an exaggerated inflammatory response to minor trauma, manifests in several disorders beyond , often complicating diagnosis and management. In (PG), a neutrophilic dermatosis frequently associated with , pathergy presents as pathergy-like undermining ulcers following minor trauma or surgery, exacerbating lesion progression and leading to rapid tissue . This phenomenon occurs in 20-50% of PG cases, where even needle pricks or incisions trigger sterile pustules or ulcers with violaceous borders, distinguishing it from infectious processes through biopsy-confirmed neutrophilic infiltrates without organisms. Postoperative PG, a subtype triggered by surgical intervention, highlights pathergy's role in susceptible patients, with reports of fatal complications such as saphenous vein graft involvement after coronary bypass. Sweet's syndrome, or acute febrile neutrophilic dermatosis, similarly exhibits pathergy through pustular or papular responses at sites of skin injury, often in the context of underlying malignancies, infections, or drug reactions. Cutaneous pathergy in this condition involves hyper-reactivity to needle pricks, resulting in dermatosis-associated lesions that mimic infection but show sterile dermal neutrophilic infiltrates on . This response underscores the shared neutrophilic pathology with PG, aiding in differential diagnosis via to confirm absence of infectious agents. Pathergy has been observed rarely in other conditions, including , where it is uncommon but can manifest through PG-like ulcers post-trauma in affected individuals. Post-surgical complications in susceptible patients, such as or , further illustrate pathergy's broader implications, particularly in those with underlying neutrophilic disorders. of pathergy involves distinguishing it from s (e.g., bacterial or fungal) and autoinflammatory syndromes through clinical history, , and demonstrating sterile inflammation with neutrophilic predominance, negative cultures, and absence of vasculitic changes specific to other entities. This approach is crucial, as misdiagnosis as can lead to unnecessary , worsening pathergy.

Epidemiology

Global Distribution

Pathergy, a nonspecific hyperreactivity of the skin and mucous membranes, exhibits marked geographic variation in prevalence, particularly in the context of (BD), where the pathergy test is a key diagnostic tool. The highest rates of positive pathergy tests are observed in regions along the ancient , spanning from the Mediterranean to . In , a high-prevalence area, pathergy positivity among BD patients has historically reached up to 80-84% in studies from the 1970s and 1980s, with rates in and other Middle Eastern countries similarly elevated, often exceeding 50-60%. These patterns align with the endemic distribution of BD itself, which peaks in these areas due to potential genetic and environmental factors. In contrast, pathergy positivity is significantly lower in Western populations, including and , where rates among BD patients typically fall below 10-30%. For instance, studies in the UK report approximately 10% positivity, while rates in and are described as rare or uncommon, often under 10%. This disparity underscores ethnic and regional differences in disease expression, with lower reactivity potentially influenced by diagnostic criteria adaptations or . Data from multinational cohorts, such as those analyzed by the International Criteria for Behçet's Disease, highlight these variations across 27 countries, confirming consistently low rates in non-endemic Western regions. Over recent decades, pathergy reactivity has shown a declining trend even in high-prevalence areas like Turkey, possibly attributable to changes in environmental exposures, , or test . Early Turkish studies reported 70-84% positivity in the 1970s-1980s, but more contemporary data from the 2010s-2020s indicate rates of 39-45%, with similar decreases observed in Iranian cohorts from 61.5% to 41%. These temporal shifts have prompted reevaluations of the pathergy test's diagnostic in updated BD criteria. Ethnic variations persist across studies from centers like the International Behçet's Center in , reinforcing the role of geography in pathergy expression.

Demographic Factors

Pathergy positivity is more frequently observed in young adults, typically those aged 20 to 40 years, aligning with the peak onset of associated conditions like during this period. Studies indicate that pathergy test results are significantly higher in patients under 40 years compared to older groups, with positivity rates declining notably after age 50 as immune reactivity diminishes with advancing age. Regarding , pathergy reactivity shows a slight predominance in , particularly in endemic regions along the , where patients exhibit higher test positivity rates than females, though this pattern is not consistent across all populations. For instance, the three-step pathergy test demonstrates a statistically significant association with , contributing to overall male bias in severe manifestations. Genetic factors play a prominent role in pathergy susceptibility, with a strong association to the allele, which confers an elevated risk in patients (pooled odds ratio of approximately 5.8 from of over 4,800 cases). This allele's prevalence is notably higher in affected individuals from countries, and homozygosity is commonly observed in familial cases, underscoring genetic clustering within families. Familial aggregation further supports , with multiple affected relatives sharing positivity in up to 20-30% of high-risk pedigrees. Other personal traits influencing pathergy include lifestyle and environmental factors, such as , which may enhance skin reactivity in some contexts by modulating function and inflammatory responses, though evidence is mixed with reports of both protective and aggravating effects on related symptoms. Additionally, urban residence correlates with higher pathergy positivity and overall compared to rural areas, potentially due to increased environmental exposures or diagnostic access, complementing broader geographic patterns of distribution.

Management

Treatment Approaches

Management of pathergy primarily involves preventive strategies to minimize trauma in susceptible individuals, as even minor skin punctures or injuries can trigger exaggerated inflammatory responses. Patients with known pathergy, particularly those with , are advised to avoid unnecessary procedures and use protective measures during medical interventions, such as pre-treatment with topical antiseptics like to reduce reaction risk. For lesions induced by pathergy, initial treatment focuses on topical corticosteroids to suppress local and promote resolution, often applied directly to erythematous papules or pustules. Wound care emphasizes sterility to prevent secondary complications, utilizing antiseptic dressings and gentle cleansing with saline or mild antiseptics; antibiotics are reserved exclusively for cases of confirmed secondary bacterial , as routine use is not recommended due to the initially sterile nature of these wounds. In the context of associated conditions like , at doses of 1-2 mg per day serves as a first-line agent to inhibit hyperactivity, effectively reducing the frequency and severity of mucocutaneous manifestations including pathergy-positive reactions. For more severe or cases, systemic immunosuppressants such as (titrated to 2.5 mg/kg/day) are employed to control broader inflammatory activity, while biologics like anti-TNF agents (e.g., at 5 mg/kg or at 40 mg every two weeks) target cytokine-driven responses in patients unresponsive to conventional therapy. Emerging therapies targeting autoinflammatory pathways show promise, with interleukin-1 (IL-1) inhibitors such as or demonstrating efficacy in suppressing pathergy-related inflammation in through blockade of IL-1β signaling.

Prognosis

The pathergy reaction is typically benign and self-resolves without long-term sequelae. In patients with , however, a positive pathergy test signifies active inflammation and is linked to heightened risk of systemic flares, including and vascular events. Trauma-induced pathergy in these individuals can precipitate organ-specific reactions, underscoring its role as a marker of potential progression. Pathergy reactivity often wanes over time, particularly with advancing age or effective management of the associated condition, leading to reduced positivity rates in longitudinal studies. Recurrence remains contingent on the frequency and nature of cutaneous trauma, with immunosuppressive therapies further diminishing responsiveness. Potential complications include chronic scarring from persistent or recurrent ulcers at pathergy sites, as seen in more severe cases involving prolonged tissue damage. In immunosuppressed individuals, such as those on therapies for , pathergy lesions carry an elevated infection risk due to impaired and . Prognostic indicators, including persistent pathergy positivity, are associated with adverse vascular outcomes like in endemic populations, signaling a need for vigilant monitoring.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK558909/
  2. https://dermnetnz.org/topics/pathergy
  3. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.639404/full
  4. https://doi.org/10.33235/wpr.30.1.55-61
  5. https://academic.oup.com/rheumatology/article-abstract/62/5/1903/6726183
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8185024/
  7. https://doi.org/10.1002/art.20334
  8. https://doi.org/10.1046/j.1365-4362.1998.00474.x
  9. https://doi.org/10.1007/s00403-009-1013-0
  10. https://doi.org/10.4049/jimmunol.177.9.6415
  11. https://doi.org/10.1136/ard.55.2.128
  12. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.613419/full
  13. https://www.mdpi.com/2227-9059/11/7/1882
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC2628050/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC8273328/
  16. https://academic.oup.com/bjd/article/146/1/168/6634292
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC7322300/
  18. https://ijdvl.com/the-oral-and-skin-pathergy-test/
  19. https://www.mdpi.com/2075-4418/13/1/41
  20. https://pubmed.ncbi.nlm.nih.gov/21365194/
  21. https://medicaljournalssweden.se/actadv/article/view/8017/11493
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC10671634/
  23. https://www.mdpi.com/1422-0067/24/22/16382
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC5610876/
  25. https://pubmed.ncbi.nlm.nih.gov/1970380/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC4169091/
  27. https://journals.lww.com/md-journal/fulltext/2024/03220/folliculitis_might_be_associated_with.20.aspx
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5442298/
  29. https://www.ncbi.nlm.nih.gov/books/NBK482223/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3528228/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC1963326/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4371674/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC2879713/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC7948547/
  35. https://www.intechopen.com/chapters/54638
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4698787/
  37. https://www.emjreviews.com/rheumatology/article/clinical-manifestations-and-diagnosis-of-behcets-syndrome-j170121/
  38. https://www.sciencedirect.com/topics/medicine-and-dentistry/pathergy
  39. https://archivesofrheumatology.org/index.php/pub/article/view/1058
  40. https://onlinelibrary.wiley.com/doi/10.1111/ijcp.14994
  41. https://pubmed.ncbi.nlm.nih.gov/19790126/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3195436/
  43. https://www.clinexprheumatol.org/article.asp?a=1295
  44. https://pubmed.ncbi.nlm.nih.gov/15515786/
  45. https://www.ncbi.nlm.nih.gov/books/NBK470257/
  46. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1134939/full
  47. https://pubmed.ncbi.nlm.nih.gov/30799530/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC8136102/
  49. https://www.clinexprheumatol.org/article.asp?a=1560
Add your contribution
Related Hubs
User Avatar
No comments yet.